mRNA-3210

DRUG2 trials

Sponsors

Moderna Therapeutics Inc., ModernaTX, Inc.

Conditions

Participants with PhenylketonuriaPhenylketonuria

Phase 1

A Dose-finding Study to Evaluate mRNA-3210 in Participants With Phenylketonuria

WithdrawnNCT06147856

ModernaTX, Inc.Phenylketonuria

Start: 2024-03-29End: 2027-08-05Updated: 2024-10-22

A Phase 1/2, First-in-Human, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of mRNA 3210 in Participants with Phenylketonuria

CompletedCTIS2023-506963-32-00

Moderna Therapeutics Inc.Participants with Phenylketonuria

End: 2024-09-12Target: 16Updated: 2024-07-16